La cadena de opciones muestra datos clave de las opciones de acciones de Tungray Technologies a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tungray Technologies..

Tungray Technologies (NASDAQ:TRSG) Bolsa, Cadena de Opciones

Tungray Technologies

Tungray Technologies Inc is an engineer-to-order company that provides custom industrial manufacturing solutions to original equipment manufacturers in the semiconductor, printer, electronics, and home appliance industries. It predominantly generates revenue through the manufacture of custom industrial manufacturing solutions, direct drive and linear DC motors, and induction welding equipment. Geographically, the company generates a majority of its revenue from Singapore and the rest from China.

Tungray Technologies Inc - Class A Ordinary Shares

Tungray Technologies Inc

Prospect Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSEC#NASDAQ">PSEC</a>) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.14 by 35.71 percent. This is a 17.39 percent decrease over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $170.72 million which missed the analyst consensus estimate of $174.29 million by 2.05 percent. This is a 15.58 percent decrease over sales of $202.22 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

PSEC

Prospect Capital Q3 EPS $0.19 Beats $0.14 Estimate, Sales $170.72M Miss $174.29M Estimate

WIIM

TELA

TELA Bio shares are trading higher. The company reported Q1 financial results

Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.56 by 8.93 percent. The company reported quarterly sales of $12.28 billion which beat the analyst consensus estimate of $11.62 billion by 5.66 percent.

INGM

Ingram Micro Holding Q1 Adj. EPS $0.61 Beats $0.56 Estimate, Sales $12.28B Beat $11.62B Estimate

TimkenSteel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTUS#NYSE">MTUS</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.12 by 41.67 percent. This is a 87.5 percent decrease over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $280.50 million which beat the analyst consensus estimate of $264.03 million by 6.24 percent. This is a 12.78 percent decrease over sales of $321.60 million the same period last year.

MTUS

TimkenSteel Q1 Adj. EPS $0.07 Misses $0.12 Estimate, Sales $280.50M Beat $264.03M Estimate

LASR

nLIGHT shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) lowers FY2025 sales outlook from $204.00 million-$212.00 million to $196.00 million-$210.00 million vs $204.43 million estimate.

Guidance

CTKB

Cytek Biosciences Lowers FY2025 Sales Guidance from $204.00M-$212.00M to $196.00M-$210.00M vs $204.43M Est

Raised Fiscal Year 2025 Guidance
<ul>
<li>Revenue is expected to be in the range of $540 to $545 million versus a previous range of $525 to $535 million.</li>
<li>Adjusted EBITDA is expected to be in the range of $68 to $70 million versus a previous range of $68 to $69 million.</li>
<li>Capital expenditures are expected to remain in the range of $15 to $20 million.</li>
</ul>

IBEX

IBEX Raises FY2025 Sales Guidance from $525.00M-$535.00M to $540.00M-$545.00M vs $530.85M Est

SHPH

Shuttle Pharmaceuticals Holdings are trading higher after the company announced FDA orphan-drug nears patient enrollment milestone for phase 2 clinical trial

PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) FY2025 Revenue expected to be more than $46.00M vs $42.23M Est

PSQH

PSQ Holdings FY2025  Revenue expected to be more than $46.00M vs $42.23M Est

IOVA

Iovance Biotherapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

AbCellera Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABCL#NASDAQ">ABCL</a>) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $4.24 million which missed the analyst consensus estimate of $7.53 million by 43.74 percent. This is a 57.45 percent decrease over sales of $9.95 million the same period last year.

ABCL

AbCellera Biologics Q1 EPS $(0.14), Inline, Sales $4.24M Miss $7.53M Estimate

Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) affirms FY2025 sales outlook from $170.00 million-$180.00 million to $170.00 million-$180.00 million vs $175.51 million estimate.

MITK

Mitek Systems Affirms FY2025 Sales Guidance of $170.00M-$180.00M vs $175.51M Est

IBEX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBEX#NASDAQ">IBEX</a>) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of $0.72 by 13.89 percent. This is a 17.14 percent increase over earnings of $0.70 per share from the same period last year. The company reported quarterly sales of $140.74 million which beat the analyst consensus estimate of $131.25 million by 7.23 percent. This is a 10.99 percent increase over sales of $126.80 million the same period last year.

IBEX Q3 Adj. EPS $0.82 Beats $0.72 Estimate, Sales $140.74M Beat $131.25M Estimate

Sutro Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRO#NASDAQ">STRO</a>) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.71) by 28.17 percent. This is a 4.21 percent increase over losses of $(0.95) per share from the same period last year. The company reported quarterly sales of $17.40 million which beat the analyst consensus estimate of $11.61 million by 49.85 percent. This is a 33.76 percent increase over sales of $13.01 million the same period last year.

STRO

Sutro Biopharma Q1 EPS $(0.91) Misses $(0.71) Estimate, Sales $17.40M Beat $11.61M Estimate

PSQ Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSQH#NYSE">PSQH</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.31) by 67.74 percent. This is a 77.27 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $6.75 million which missed the analyst consensus estimate of $6.83 million by 1.19 percent. This is a 94.75 percent increase over sales of $3.47 million the same period last year.

PSQ Holdings Q1 EPS $(0.10) Beats $(0.31) Estimate, Sales $6.75M Miss $6.83M Estimate

Kingsway Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFS#NYSE">KFS</a>) reported quarterly losses of $(0.13) per share. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $28.35 million in sales this quarter. This is a 8.20 percent increase over sales of $26.20 million the same period last year.

Kingsway Financial Servs Q1 EPS $(0.13) Down From $(0.09) YoY, Sales $28.35M Up From $26.20M YoY

CARG

CarGurus shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results and issued Q2 adjusted EPS guidance above estimates.

Nelnet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNI#NYSE">NNI</a>) reported quarterly earnings of $2.39 per share which beat the analyst consensus estimate of $1.92 by 24.48 percent. This is a 32.04 percent increase over earnings of $1.81 per share from the same period last year. The company reported quarterly sales of $398.49 million which beat the analyst consensus estimate of $393.27 million by 1.33 percent. This is a 3.40 percent increase over sales of $385.38 million the same period last year.

Nelnet Q1 Adj. EPS $2.39 Beats $1.92 Estimate, Sales $398.49M Beat $393.27M Estimate

KLXE

KLX Energy Services shares are trading lower after the company reporter worse-than-expected Q1 financial results

Cantaloupe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTLP#NASDAQ">CTLP</a>) lowers FY2025 sales outlook from $308.00 million-$322.00 million to $302.00 million-$308.00 million vs $309.90 million estimate.

CTLP

Cantaloupe Lowers FY2025 Sales Guidance from $308.00M-$322.00M to $302.00M-$308.00M vs $309.90M Est

Legal

Press Releases

TRSG Announcement: If You Have Suffered Losses in Tungray Technologies Inc (NASDAQ: TRSG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

TRSG Investor News: Rosen Law Firm Encourages Tungray Technologies Inc Investors to Inquire About Securities Class Action Investigation - TRSG

TRSG Investor News: If You Have Suffered Losses in Tungray Technologies Inc (NASDAQ: TRSG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Comments

Tungray Technologies

Tungray Technologies (TRSG) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL